

of core, E1, HVRI and NS5b regions. *J. Virology* 75:3004-3009, 2001.

4) Sugauchi F, Mizokami M, Orito E, Ohno T, Kato H, Suzuki S, Kimura Y, Ueda R, Butterworth LA, Cooksley WGE : A novel variant genotype C of hepatitis B virus identified in isolates from Australian Aborigines: complete genome sequence and phylogenetic relatedness. *J Gen Virol* 82: 883-892, 2001.

5) Ding X, Mizokami M, Yao G, Xu B, Orito E, Ueda R, Nakanishi M : Hepatitis B Virus Genotype Distribution among Chronic Hepatitis B Virus Carriers in Shanghai, China. *Intervirology* 44(1):43-7, 2001.

6) Orito E, Ichida T, Sakugawa H, Sata M, Horike N, Hino K, Okita K, Okanoue T, Iino S, Tanaka E, Suzuki K, Watanabe H, Hige S, Mizokami M : Geographic distribution of hepatitis B virus genotype in patients with chronic HBV infection in Japan. *Hepatology* 34: 590-594, 2001.

7) Nakano T, Shapiro CN, Hadler SC, Casey JL, Mizokami M, Orito E, Robertson B. Characterization of hepatitis D virus genotype III among Yuca Indians in Venezuela. *J Gen Virol* 82:2183-2189, 2001.

8) Kato H, Orito E, Sugauchi F, Ueda R, Gish RG, Usuda S, Miyakawa Y, Mizokami M : Determination of hepatitis B virus genotype G by polymerase chain reaction with hemi-nested primers. *J Virol Methods* 98: 153-159, 2001.

9) Iijima Y, Kato T, Miyakawa H, Ogino M, Mizuno M, Sugihara K, Ando T, Fujiwara K, Orito E, Ueda R, Mizokami M : Effect of interferon therapy on Japanese chronic hepatitis C virus patients with anti-liver/kidney microsome autoantibody type I. *J Gastroenterol Hepatol* 16(7):782-8, 2001.

10) Yoshioka K, Kobayashi M, Orito E, Watanabe K, Yano M, Sameshima Y, Kusakabe A, Hirofuji H, Fuji A, Kuriki j, Arao M, Murase K, Mizokami M, Kakumu S, the IFN Treatment Group of Affiliated Hospitals of the Third Department of Internal Medicine at Nagoya university School of medicine : Biochemical response to interferon therapy correlates with interferon sensitivity-determining region in hepatitis C virus genotype 1b infection. *J. Viral Hepatitis* 8:421-429, 2001

泉

1) Asahina Y, Izumi N, Uchihara M, Noguchi O, Tsuchiya K, Hamano K, Kanazawa N, Itakura J, Miyake S, Sakai T : A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta. *Hepatology* 2001;34:277-384.

2) Izumi N, Asahina Y, Noguchi O, Uchihara M, Kanazawa N, Itakura J, Himeno Y, Miyake S, Sakai T, Enomoto N : Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. *Cancer* 2001 ; 91 : 949-956.

3) Izumi N : How to improve virological sustained response rate by interferon therapy for patients with chronic hepatitis C. *J Gastroenterol*, 2001 ; 36 : 281-283

4) Izumi N, Kumada H, Hashimoto N, Harada H, Imawari M, Zeniya M, Toda G : Rapid decrease of plasma HCV RNA in early phase of twice daily administration of 3MU dose interferon-beta in patients with genotype 1b hepatitis C infection- A multicenter randomized study. *Dig Dis Sci*, 2001 ; 46:516-523.

5) Watanabe H, Enomoto N, Nagayama K, Izumi N, Marumo F, Sato C, Watanabe M : Number and position of mutations in the interferon(IFN) sensitivity-determining region of the gene for nonstructural protein 5A correlate with IFN efficacy in hepatitis C virus genotype 1b infection. *J Infect Dis*, 2001;183:1195-1203.

6) Nagayama K, Enomoto N, Izumi N, Kurosaki M, Miyasaka Y, Watanabe H, Itakura J, Chen CH, Tazawa J, Hoshino Y, Ikeda T, Marumo F, Sato C : Sequences in the NS5A protein of hepatitis C virus and the serum alanine aminotransferase response to interferon therapy in Japanese patients. *Gut* 2001 ; 48:830-835.

7) Nagayama K, Enomoto N, Miyasaka Y, Kurosaki M, Chen CH, Sakamoto N, Nakagawa M, Sato C, Tazawa J, Ikeda T, Izumi N, Watanabe M ; Overexpression of interferon  $\gamma$ -inducible protein 10 in the liver of patients with type I autoimmune hepatitis identified by suppression subtractive hybridization. *Am J Gastroenterol*, 2001;96:2211-2217.

8) Y Miyasaka, N Enomoto, K Nagayama, N Izumi, F Marumo, M Watanabe, C Sato : Analysis of differentially expressed genes in

human hepatocellular carcinoma using suppression subtractive hybridization.

*Br J Cancer*, 2001;85:228-234.

9) Itakura J, Nagayama K, Enomoto N, Sakamoto N, Tazawa J, Izumi N, Marumo F, Sato C. CD81 nucleotide mutation in hepatocellular carcinoma and lack of CD81 polymorphism in patients at stages of hepatitis C virus infection. *J Med Virol*. 2001 Jan;63(1):22-8.

四柳

1) H Yotsuyanagi, K Yasuda, K Moriya, Y Shintani, H Fujie, T Tsutsumi, N Nojiri, T Fuji, H Hoshino, K Shimoda, K Iino, S Kimura, S Iino, K Koike : Frequent presence of HBV in the sera of HBs Ag-negative, anti-HBc-positive blood donors. *Transfusion* 41:1093-1099, 2001

2) E Orito, M Mizokami, H Sakugawa, K Michitaka, K Ishikawa, T Ichida, T Okanoue, H Yotsuyanagi, S Iino, for the Japan HBV Genotype Research Group : A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. *Hepatology* 33:218-223, 2001

3) H Yotsuyanagi, Y Shintani, K Moriya, H Fuji, T Tsutsumi, T Kato, K Nishioka, T Takayama, M Makuuchi, S Iino, S Kimura, Koike K : Virologic analysis of non-B, non-C hepatocellular carcinoma in Japan: frequent involvement of hepatitis B virus. *J. Inf. Dis.* 181:1920-1928, 2001